Phase III, double-blind trial of lasofoxifene in postmenopausal with low or normal bone mineral density

Trial Profile

Phase III, double-blind trial of lasofoxifene in postmenopausal with low or normal bone mineral density

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2015

At a glance

  • Drugs Lasofoxifene (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Acronyms OPAL
  • Most Recent Events

    • 16 Sep 2015 Results will be presented at the North American Menopause Society (NAMS) Annual Meeting 2015, according to a Sermonix Pharmaceuticals media release.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top